The commencement of Dilaforette’s Phase II trial with sevaparin in patients with sickle-cell disease is encouraging and marks the first milestone in Ergomed’s Orphan drug co-development deal. Data is expected in H2 2016. The five current co-development deals offer potentially very attractive returns with clinical data from 4 due between now and the end of 2016, providing upside potential to our 290p TP. We remain at Buy and look forward to data from the group’s co-development deals.
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Co-development partner initiates Phase II
- Published:
13 Oct 2015 -
Author:
Sheena Berry -
Pages:
3
The commencement of Dilaforette’s Phase II trial with sevaparin in patients with sickle-cell disease is encouraging and marks the first milestone in Ergomed’s Orphan drug co-development deal. Data is expected in H2 2016. The five current co-development deals offer potentially very attractive returns with clinical data from 4 due between now and the end of 2016, providing upside potential to our 290p TP. We remain at Buy and look forward to data from the group’s co-development deals.